TBE/iStock Editorial via Getty Images
Update 7:05am: Adds shares, MorphoSys statement.
A new safety risk related to Morphosys's (NASDAQ:MOR) pelabresib, an experimental treatment for myelofibrosis, could complicate the company's planned $3B sale to Novartis (NYSE:NVS). MorphoSys shares fell 1.5% in premarket trading.
“Physicians involved with MorphoSys’ completed Phase 3